Roxanne Duan
Geen lopende functies
Profiel
Roxanne Duan is the founder of Infinity Pharmaceuticals, Inc. She previously held positions as Principal at Human Genome Sciences, Inc., President and Vice President-Research & Development at Adlyfe, Inc., and Vice President-Research at Functional Genetics, Inc.
Eerdere bekende functies van Roxanne Duan
Bedrijven | Functie | Einde |
---|---|---|
INFINITY PHARMACEUTICALS, INC. | Oprichter | - |
Functional Genetics, Inc.
Functional Genetics, Inc. Miscellaneous Commercial ServicesCommercial Services Functional Genetics, Inc. operated as a biotechnology company. Its products facilitate simultaneous targeting of multiple co-morbid pathogens with a single drug. The company provided antiviral drugs that demonstrate beneficial activity against various viruses, included HIV, RSV, influenza, hepatitis viruses, herpes and bio-threat pathogens. Functional Genetics was founded in 1987 and was headquartered in Palo Alto, CA. | Hoofd Techniek/Wetenschap/O&O | - |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | - |
Adlyfe, Inc.
Adlyfe, Inc. Medical DistributorsDistribution Services Adlyfe, Inc. is a privately held early stage biotechnology company that utilizes novel and proprietary peptide technology to develop solutions for early detection of protein misfolding diseases. It offers Pronucleon, a platform technology using custom-synthesized peptides that allow signal amplification to map the surface of rare proteins. The firm's technology detects the sequence and the conformation of amyloid proteins, to create sensitive and specific detection methods that allow early stage diagnosis and disease progression monitoring. Adlyfe was founded in 2003 by Richard O. Cliff and is headquartered in Rockville, MD. | President | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
INFINITY PHARMACEUTICALS, INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Adlyfe, Inc.
Adlyfe, Inc. Medical DistributorsDistribution Services Adlyfe, Inc. is a privately held early stage biotechnology company that utilizes novel and proprietary peptide technology to develop solutions for early detection of protein misfolding diseases. It offers Pronucleon, a platform technology using custom-synthesized peptides that allow signal amplification to map the surface of rare proteins. The firm's technology detects the sequence and the conformation of amyloid proteins, to create sensitive and specific detection methods that allow early stage diagnosis and disease progression monitoring. Adlyfe was founded in 2003 by Richard O. Cliff and is headquartered in Rockville, MD. | Distribution Services |
Functional Genetics, Inc.
Functional Genetics, Inc. Miscellaneous Commercial ServicesCommercial Services Functional Genetics, Inc. operated as a biotechnology company. Its products facilitate simultaneous targeting of multiple co-morbid pathogens with a single drug. The company provided antiviral drugs that demonstrate beneficial activity against various viruses, included HIV, RSV, influenza, hepatitis viruses, herpes and bio-threat pathogens. Functional Genetics was founded in 1987 and was headquartered in Palo Alto, CA. | Commercial Services |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |